- Home
- ANDE vs ETNB Comparison
ANDE vs ETNB Comparison
Compare ANDE & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANDE
- ETNB
- Stock Information
- Founded
- ANDE 1947
- ETNB 2018
- Country
- ANDE United States
- ETNB United States
- Employees
- ANDE N/A
- ETNB N/A
- Industry
- ANDE Farming/Seeds/Milling
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ANDE Industrials
- ETNB Health Care
- Exchange
- ANDE Nasdaq
- ETNB Nasdaq
- Market Cap
- ANDE 1.4B
- ETNB 1.5B
- IPO Year
- ANDE N/A
- ETNB 2019
- Fundamental
- Price
- ANDE $41.29
- ETNB $14.85
- Analyst Decision
- ANDE Buy
- ETNB Buy
- Analyst Count
- ANDE 3
- ETNB 10
- Target Price
- ANDE $51.67
- ETNB $22.31
- AVG Volume (30 Days)
- ANDE 515.3K
- ETNB 9.4M
- Earning Date
- ANDE 11-03-2025
- ETNB 11-06-2025
- Dividend Yield
- ANDE 1.89%
- ETNB N/A
- EPS Growth
- ANDE N/A
- ETNB N/A
- EPS
- ANDE 2.35
- ETNB N/A
- Revenue
- ANDE $11,539,093,000.00
- ETNB N/A
- Revenue This Year
- ANDE $9.10
- ETNB N/A
- Revenue Next Year
- ANDE $2.78
- ETNB N/A
- P/E Ratio
- ANDE $17.57
- ETNB N/A
- Revenue Growth
- ANDE N/A
- ETNB N/A
- 52 Week Low
- ANDE $31.03
- ETNB $4.16
- 52 Week High
- ANDE $51.58
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- ANDE 59.31
- ETNB 80.12
- Support Level
- ANDE $39.16
- ETNB $14.67
- Resistance Level
- ANDE $40.66
- ETNB $14.93
- Average True Range (ATR)
- ANDE 1.12
- ETNB 0.13
- MACD
- ANDE 0.10
- ETNB 0.19
- Stochastic Oscillator
- ANDE 92.54
- ETNB 97.08
About ANDE Andersons Inc. (The)
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).